University of Texas System

Aronex Pharmaceuticals, Inc.

Other

Consiglio Nazionale Delle Ricerche

University of North Texas

University of Mississippi

Gabriel Lopez-Berestein

Ana Maria Tari

Reeta Mehta

Roman Perez-Soler

Ralph B Arlinghaus

Anil K Sood

Kapil Mehta

Abdul R Khokhar

Rudolph L Juliano

Roy L Hopfer

Bulent Ozpolat

Robert P Lenk

Jack A Roth

Lin Ji

Evan M Hersh

Jim Klostergaard

Jacki Lin

Mar Tormo

Jiaxin Liu

Dai Lu

Tong Sun

Victor Fainstein

Waldemar Priebe

David L Volk

William G Bornmann

Laszlo Prokai

Charles Keller

Vittorio De Franciscis

Menashe Bar-Eli

Andras G Lacko

Francis Ali-Osman

Jansina Fok

Timothy J McDonnell

Kevin N Dalby

Ariel Fernandez

Arturo Chavez-Reyes

Yolanda Gutierrez-Puente

Lokesh Ganesh L Rao

Yun Wu

Lingegowda S Mangala

Alan C Hayman

Walter J McConathy

Robert Lenk

Maya P Nair

Jim Turpin

Stanley D Tucker

Angela Sanguino

Mathoor Sivaramakrishnan

Zheng-Hong Peng

Albert B Deisseroth

Jiney Jose

Amit Verma

Alan C Hayman, Deceased

Hui-Wen Lo

Sushovan Guha

Gamil Antoun

John K Buolamwini

William M Merritt

Olanike Akande

Robert P Link

Paola Amero

Burcu Aslan

Charles N Landen

Cristian Rodriguez-aguayo

Rahul Mitra

Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

DNA aptamers and use thereof for the treatment of cancer

Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the chitosan nanoparticles are coated with polylactic acid. Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease are also disclosed. For example, the treatment of ovarian cancer in a subject by inhibiting the expression of ZNF034 is disclosed.

Dual assembly nanoparticles

Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.

Compositions and methods for treating cancer

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell via a neutral (non-charged) liposome. These methods may be used to treat a disease, such as cancer.

Delivery of siRNA by neutral lipid compositions

A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.

Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.

HDL particles for delivery of nucleic acids

This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.

Methods and compositions related to wrapping of dehydrons

A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).

Methods for treating cancer targeting transglutaminase

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein.

Therapeutic targeting of interleukins using siRNA in neutral liposomes

The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.

Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.

Liposomal phosphodiester, phophorothioate, and p-ethoxy oligonucleotides

The present invention provides short antisense oligonucleotide compositions and methods for their use in the treatment of Bcl-2-associated diseases like cancer, such as follicular lymphoma (FL). The antisense oligonucleotides contain sequences that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. The use of novel short antisense oligonucleotides, from 7 bases to 9 bases in length, is described in this invention. The invention also describes certain specific sequences which are longer than 9 bases and are 11 or 15 bases long. Used alone, or in conjunction with other antisense oligonucleotides, these antisense oligonucleotide compositions inhibit the proliferation of cancer cells.

Small oligonucleotides with anti-tumor activity

The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crk1 nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.

Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1

The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.

Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides

Growing community of inventors

Bellaire, TX, United States of America

Gabriel Lopez-Berestein